There was no significant difference in levels of CD33+CD11b+HLA-DR−/lowCD14+ monocytic myeloid cells (MMCs) in CRC patients compared to HDs (CRC: 2.4 ± 0.5%; HD: 3.2 ± 0.5%; Figure 1B). Here, CD33 is linked to colorectal carcinoma.